Please use this identifier to cite or link to this item:
|Title:||The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation|
Cámara, R. de la
Nieto, J. B.
Vallejo, J. C.
Urbano Ispizua, Álvaro
Díez-Martín, J. L.
Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
|Publisher:||Public Library of Science (PLoS)|
|Abstract:||The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (≤(GT)15) for the (GT)n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0140454|
|It is part of:||PLoS One, 2015, vol. 10, num. 10|
|Appears in Collections:||Articles publicats en revistes (Medicina)|
This item is licensed under a Creative Commons License